Inflammatory Bowel Disease Conference

Saturday, October 1, 2022, 7:00 AM - 12:00 PM, University of Cincinnati, Nippert West Pavilion, 2700 Bearcat Way, Cincinnati, OH

AMA PRA Category 1 Credits™ (3.50 hours), AMA PRA Category 1 Credits™ Designated (3.50 hours)


The University of Cincinnati Inflammatory Bowel Diseases Course teaches healthcare practitioners how to provide personalized treatment for the right patient at the right time. It will provide an in-depth overview of how to treat and monitor patients with Crohn’s Disease and Ulcerative Colitis.
Lectures will be given by expert inflammatory bowel disease gastroenterologists and colorectal surgeons.

For more information and to register, please visit https://www.uc.edu/about/event-services/inflammatory-bowel-disease-conference.html.

Registration Fee: $99.00

1. Identify the rationale for positioning of biologic therapies and small molecules for Crohn's disease.
2. Implement a transition plan for an adolescent with IBD from pediatrics to adult care.
3. Identify the rationale for positioning of biologic therapies and small molecules for ulcerative colitis.
4. Implement endoscopic techniques when performing a pouchoscopy and descried how to perform an adequate pouchoscopy report.
5. Implement disease monitoring strategies using patient reported outcomes, biomarkers, endoscopy, and histology.
6. Describe the treatment options available for perianal fistulizing Crohn’s Disease.

The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Cincinnati designates this live activity for a maximum of 3.5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The opinions expressed during the live activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati. The information is presented for the purpose of advancing the attendees' professional development.

See website for nearby hotels.

Disclosure of Ineligible Relationships (COI) Policy

In accordance with the ACCME Standards for Integrity and Independence and the University of Cincinnati policy, all faculty, planning committee members, and other individuals, who are in a position to control content, are required to disclose all relationships with ineligible companies (commercial interest) within the last 24-months. The ACCME requires us to disqualify individuals who refuse to provide this information from involvement in the planning and implementation of accredited continuing education. All educational materials are reviewed for fair balance,  scientific objectivity, and levels of evidence.

The faculty and planners reported the following financial relationships, or relationships to products or devices, they have with ineligible companies (commercial interests) related to the 
content of this CME activity. The noted relationships below have been mitigated and not relevant to this presentation.

Faculty Disclosures:
Anita Afzali, MD, MPH, MHCM
Professor of Medicine
Executive Vice Chair, ACMO
University of Cincinnati 

Consulting/Speaking/Grants: Abbvie, Janssen, BMS, Takeda, Pfizer, Lilly. Founder/Board Member: IBD Horizons, Scrubs & Heels. Consulting/Scientific Board: TLL Pharma                                                                             

Kara De Felice, MD                                                          
Associate Professor of Medicine
Program Director
University of Cincinnati                                        

Honorary Speaker, Advisor: Abbvie, BMS, Honorary Speaker: Takeda

Amy Lightner, MD   
Associate Professor
Cleveland Clinic

Consultant: Takeda, Boomerang, Ossium, Direct Biologics, Mesoblast

Jennifer Hellmann, MD (No Relevant Relationships)                            
Assistant Professor of Pediatrics
Cincinnati Children's Hospital Medical Center

Jami Kinnucan, MD
Senior Associate Consultant 
Mayo Jacksonville                             

Advisory Board/Consultant: Abbvie, Janssen, Pfizer, BMS

Jennifer Seminerio, MD
Director of Inflammatory Bowel Disease
University of South Florida

Speaker/Consultant: Abbvie, Janssen, Pfizer, Takeda  

 

Planning Committee Members:
Kara De Felice, MD                                                          
Associate Professor of Medicine
Program Director
University of Cincinnati                                        

Honorary Speaker, Advisor: Abbvie, BMS, Honorary Speaker: Takeda

Heather Griffin (No Relevant Relationships)
Program Coordinator
Conference & Event Services
University of Cincinnati

Katy Marston (No Relevant Relationships)
Program Coordinator
University of Cincinnati

Susan Tyler, PhD, CHCP, CMP (No Relevant Relationships)                    
CCPD/CME Associate Dean
University of Cincinnati                          

Suzanne Matthey (No Relevant Relationships) 
Program Coordinator, CCPD/CME Office
University of Cincinnati

Bruce Gebhardt, MD (No Relevant Relationships)                              
Physician Reviewer
University of Cincinnati                                 

Robert Ellis, MD (No Relevant Relationships)                              
Physician Reviewer                                  
University of Cincinnati

Mitigation of Relevant Financial Relationships

The University of Cincinnati adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests) over the last 24-months. All relevant relationships have been mitigated prior to the commencement of the activity.

Information regarding the new updated ACCME Standards for Integrity and Independence in Accredited Continuing Education can be found on the ACCME website.

Saturday, October 1, 2022